Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bcl-2 controls dendritic cell longevity in vivo.

Adam Nopora1, Thomas Brocker

  • 1Institute for Immunology, Ludwig-Maximilians University, Munich, Germany.

Journal of Immunology (Baltimore, Md. : 1950)
|September 10, 2002
PubMed
Summary

Down-regulation of Bcl-2 controls dendritic cell (DC) longevity. Enhancing Bcl-2 in DCs boosts immune responses and improves DC vaccine efficacy, offering new therapeutic strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LUBAC modulates CBM complex functions downstream of TRAF6 in T cells.

Nature communications·2025
Same author

Assessing Extracellular Vesicle Turnover In Vivo Using Highly Sensitive Phosphatidylserine-Binding Reagents.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Two-dimensional analysis of plasma-derived extracellular vesicles to determine the HER2 status in breast cancer patients.

Breast cancer research : BCR·2025
Same author

Procoagulant platelet activation promotes venous thrombosis.

Blood·2024
Same author

Plasmacytoid dendritic cells control homeostasis of megakaryopoiesis.

Nature·2024
Same author

CircRNAs in Pancreatic Cancer: New Tools for Target Identification and Therapeutic Intervention.

Cancer genomics & proteomics·2024

Area of Science:

  • Immunology
  • Cell Biology

Background:

  • Dendritic cells (DCs) down-regulate anti-apoptotic Bcl-2 protein during maturation in vivo.
  • This down-regulation suggests a mechanism controlling DC longevity and immune response modulation.

Purpose of the Study:

  • To investigate the role of Bcl-2 in DC longevity and immune regulation.
  • To assess the impact of dysregulating Bcl-2 expression on DC function and immune responses.

Main Methods:

  • Generation of transgenic mice with human Bcl-2 specifically expressed in DCs under the CD11c promoter.
  • In vivo bromodeoxyuridine labeling and adoptive DC transfer studies.
  • Evaluation of immune responses, including CD4+ T cell and humoral immunity, and DC vaccine efficacy.

Main Results:

  • Transgenic mice exhibited increased frequencies and numbers of DCs.
  • Mature Bcl-2 transgenic DCs showed increased survival and turnover in vivo.
  • Elevated CD4+ T cell and humoral immune responses were observed in transgenic animals.
  • Bcl-2 transgenic DC vaccines induced significantly greater expansion of antigen-specific cytotoxic T lymphocytes (CTLs) and enhanced in vivo cytotoxicity.

Conclusions:

  • Down-regulation of Bcl-2 is a key regulator of dendritic cell longevity.
  • Modulating Bcl-2 levels in DCs directly impacts immune responses and enhances DC vaccine effectiveness.
  • Targeting Bcl-2 in DCs presents a promising strategy for improving immunotherapy and vaccine development.

Related Experiment Videos